Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) released its earnings results on Wednesday, August, 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.08. The firm had revenue of $2.31 million for the quarter, compared to analysts' expectations of $1.98 million. During the same period last year, the firm earned ($0.23) EPS. View Synergy Pharmaceuticals' Earnings History.

10 analysts have issued 12 month price targets for Synergy Pharmaceuticals' stock. Their predictions range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $8.90 in the next year. View Analyst Ratings for Synergy Pharmaceuticals.

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (9/13/2017)
• 2. HC Wainwright analysts commented, "We note that the launch of Trulance appears to be progressing on multiple fronts, with the company having reached 66% of its targeted prescriber base and over 90% of the high-volume prescribers (deciles 8-10). According to QuintilesIMS data, as of mid-2017 over 12,600 Trulance prescriptions had been filled and total monthly prescription volume has increased on average over 182% month-over-month during that period. Over 32% of all high prescribers had written a Trulance prescription since the drug was launched earlier this year, with an average increase for all prescribers of approximately 140% month-over-month. Trulance achieved 6.8% new-to-brand prescription (NBRx) total market share and 12% NBRx market share among gastroenterologists. Importantly, about 55% of new Trulance prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment and 45% were patients who converted from other branded prescription treatments." (8/10/2017)
• 3. Cantor Fitzgerald analysts commented, "Management upbeat about early returns. SGYP reported 2Q17 results and posted a new corporate presentation to provide an update of the Trulance launch (here). We spoke with management (no results call was held) to hear its views regarding how the launch is proceeding. Acknowledging the inherent positive bias of company managements that have launched their inaugural product, we believe metrics provided by SGYP may, however, show an objective snapshot of the launch." (8/10/2017)
• 4. BTIG Research analysts commented, "With the US launch of Trulance (3 mg plecanatide, for the treatment of chronic constipation) now officially underway, investor focus now turns to the ramp for Trulance in the US market. We continue to believe management is up to the task of successfully launching Trulance via its hybrid sales model (utilizing an experienced contract sales force of ~150 - 200 reps), which is expected to target ~27,000 high-prescribing physicians. While we believe formulary access for Trulance could take up to 6 months, we think most insurance plans will put Trulance on a Tier 3 co-pay, with the Co. offering its 'savings to go' program as an offset. Our channel checks with several local pharmacies in NYC this morning suggest that this program will enable patients to get access to Trulance at a much lower cost (no more than $25 per Rx). Management also recently highlighted at an investor conference earlier today that a nationwide sampling program is underway. In sum, we expect the launch of Trulance to lead to more patients switching from OTC laxatives to Rx treatments, with Trulance leading to an expansion of the overall Rx market." (3/21/2017)

Synergy Pharmaceuticals saw a decrease in short interest in the month of September. As of September 29th, there was short interest totalling 62,729,902 shares, a decrease of 6.1% from the September 15th total of 66,785,698 shares. Based on an average daily trading volume, of 4,268,901 shares, the short-interest ratio is currently 14.7 days. Currently, 28.0% of the company's stock are short sold.

Some companies that are related to Synergy Pharmaceuticals include Five Prime Therapeutics (FPRX), MyoKardia (MYOK), Ascendis Pharma A/S (ASND), Clinigen Group PLC (CLIN), Dynavax Technologies Corporation (DVAX), Acorda Therapeutics (ACOR), Sangamo Therapeutics (SGMO), Epizyme (EPZM), Lexicon Pharmaceuticals (LXRX), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), REGENXBIO (RGNX), Athenex (ATNX), Omeros Corporation (OMER), Flexion Therapeutics (FLXN), Retrophin (RTRX) and Amarin Corporation PLC (AMRN).

Synergy Pharmaceuticals' management team includes the folowing people:

• Gary S. Jacob Ph.D., Chairman of the Board, President, Chief Executive Officer
• Gary G. Gemignani, Chief Financial Officer, Executive Vice President
• Marino Garcia, Executive Vice President, Chief Strategy Officer
• Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer
• Troy Hamilton, Executive Vice President, Chief Commercial Officer
• Melvin K. Spigelman M.D., Lead Independent Director
• Thomas H. Adams Jr. Ph.D., Independent Director
• John P. Brancaccio CPA, Independent Director
• Timothy S. Callahan, Independent Director
• Richard J. Daly, Independent Director

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $2.88.